Compare FERG & A Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FERG | A |
|---|---|---|
| Founded | 1887 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous | Biotechnology: Laboratory Analytical Instruments |
| Sector | Miscellaneous | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.3B | 38.0B |
| IPO Year | 2024 | 1999 |
| Metric | FERG | A |
|---|---|---|
| Price | $220.44 | $173.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 15 |
| Target Price | ★ $268.54 | $161.47 |
| AVG Volume (30 Days) | 1.2M | ★ 1.7M |
| Earning Date | 06-02-2026 | 05-27-2026 |
| Dividend Yield | ★ 1.39% | 0.92% |
| EPS Growth | ★ 9.26 | 3.16 |
| EPS | ★ 5.56 | 3.55 |
| Revenue | ★ $30,762,000,000.00 | $4,472,000,000.00 |
| Revenue This Year | $7.98 | $8.45 |
| Revenue Next Year | $5.86 | $6.13 |
| P/E Ratio | ★ $39.60 | $48.68 |
| Revenue Growth | 3.80 | ★ 6.43 |
| 52 Week Low | $212.13 | $108.35 |
| 52 Week High | $271.64 | $174.77 |
| Indicator | FERG | A |
|---|---|---|
| Relative Strength Index (RSI) | 42.98 | 75.01 |
| Support Level | $218.91 | $124.23 |
| Resistance Level | $231.40 | N/A |
| Average True Range (ATR) | 4.87 | 4.55 |
| MACD | 0.54 | 2.02 |
| Stochastic Oscillator | 43.91 | 94.18 |
Ferguson distributes plumbing and HVAC products to North American repair, maintenance, and improvement, new construction, and civil infrastructure markets. It serves over 1 million customers and sources products from 37,000 suppliers. Ferguson engages customers through approximately 1,700 North American branches, over the phone, online, and in residential showrooms. The firm sold its UK business in 2021 and is now solely focused on the North American market.
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and diagnostics, cross lab operations consisting of consumables and services, and applied end markets. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.